Definitive Contract 75A50120C00198
Award Date 9/30/20
Potential Completion Date 6/30/26
Potential Value $16M
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not listed
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Walsh Healy Act
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a cost-plus-fixed-fee contract valued at $299.0 million to Mapp Biopharmaceutical, Inc. on September 28, 2022, for the development of MBP091, an immunotherapy candidate for treating Marburg virus infection. This definitive contract, with an ultimate completion date of July 31, 2036, originated from a Biomedical Advanced Research and Development Authority (BARDA) broad agency announcement soliciting proposals for...
- This is a cost-plus-fixed-fee definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a San Diego-based biotechnology company. The contract, which has a potential value of $7,486,450.79, is for an expanded access protocol for the drug ZMapp to treat viral hemorrhagic fevers like Ebola, Marburg, and Lassa. Mapp Biopharmaceutical is a prime contractor for ASPR, having...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense to Mapp Biopharmaceutical, Inc., a San Diego-based biotechnology company. The firm-fixed-price purchase order, with a potential value of $149,998.71, is for research and development efforts related to STTR Phase I work. Mapp Biopharmaceutical has extensive experience providing therapeutic interventions and medical...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $28.99 million cost-plus-fixed-fee definitive contract to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.) on September 9, 2019, with completion targeted for August 17, 2024. The contract supports the production of monoclonal antibody (MAB)-based therapeutics directed against botulinum neurotoxin serotype F subtypes, encompassing work across the diverse spectrum of highly variable...
- The U.S. Army's Research, Development and Engineering Command awarded a Small Business Technology Transfer (STTR) Phase II contract to Mapp Biopharmaceutical, Inc., a San Diego-based biotechnology firm specializing in antibody-based therapeutics and medical countermeasures against infectious diseases. The $1.5 million definitive contract, awarded July 28, 2020, with completion targeted for February 28, 2023, operates under a cost-plus-fixed-fee structure and includes a total small business...
- The Defense Health Agency (DHA) awarded a $110.5 million delivery order to Mapp Biopharmaceutical, Inc. for the supply of monoclonal antibodies and viral recombinant antigens. This firm fixed-price delivery order, issued on June 6, 2025, with an ultimate completion date of December 4, 2025, represents work performed at Mapp's San Diego, California location. The award carries no set-aside designation and reflects Mapp's competitive standing as a critical federal partner specializing in...
- This is a $30,559,760.00 cost-plus-fixed-fee delivery order awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Manufacturing Operations Baltimore LLC, a for-profit manufacturer of medical countermeasures. The contract is for the development of the MAPP biopharmaceutical Viral Hemorrhagic Fever (VHF) Medical Countermeasure (MCM) platform. This work is being performed under the Centers for Innovation in...
- Battelle Memorial Institute was awarded a $5.9 million delivery order on September 29, 2023, to provide testing services supporting the translational development of next-generation botulism therapeutic products for the Office of the Assistant Secretary for Preparedness and Response (ASPR). The contract is a cost-plus-fixed-fee delivery order with an ultimate completion date of April 5, 2027, and carries no set-aside designation. Work will be performed in Columbus, Ohio. ASPR, a component of...
- The Office of the Assistant Secretary for Preparedness and Response awarded a $124.5 million firm fixed-price definitive contract to Elusys Therapeutics Inc. on May 1, 2024, for the supply and delivery of ANTHIM (obiltoxaximab), a monoclonal antitoxin therapeutic. The contract, which extends through December 31, 2028, is being performed at the contractor's facility in Parsippany, New Jersey. This award reflects the federal government's commitment to maintaining strategic medical...
- This is a definitive contract awarded by the Department of the Army's Joint PEO Chemical and Biological Defense, a defense agency, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The $366,290,602.35 cost-plus-fixed-fee contract is for the Medical Countermeasures Advanced Development and Manufacturing (MCM ADM) Capability, with a period of performance through October 31, 2023. As a prime contractor, Resilience has provided a range of goods and services related...